OX Biomed

Oxford Biomedica is a leading quality-led cell and gene therapy contract development and manufacturing organization (CDMO) with a specialized focus on lentiviral vectors. The company pioneered the first FDA and EMA approved lentiviral vector-based gene therapy and provides end-to-end capabilities from process development to commercial-scale manufacturing. Beyond its CDMO services, Oxford Biomedica maintains a legacy pipeline of gene therapy candidates for ocular and neurological diseases. The company is well-known for its high-profile manufacturing partnerships, including its critical role in producing the AstraZeneca COVID-19 vaccine.